deltatrials
Completed PHASE3 INTERVENTIONAL NCT00003701

Combination Chemotherapy in Treating Patients With Bladder Cancer

A Phase III Randomized Trial of Either M-VAC or Paclitaxel + Carboplatin as Postoperative Adjuvant Therapy in Patients With Muscle-Invasive Transitional Cell Carcinoma of the Bladder at High-Risk for Relapse

Sponsor: Eastern Cooperative Oncology Group

Updated 7 times since 2017 Last updated: Jun 13, 2023 Started: Apr 2, 1999 Primary completion: Aug 31, 2001 Completion: Jun 15, 2007
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00003701, this PHASE3 trial focuses on Bladder Cancer and Urethral Cancer and remains completed. Sponsored by Eastern Cooperative Oncology Group, it has been updated 7 times since 1999, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotCompleted~Jun 2018 – ~Feb 2019 · 8 months · monthly snapshotCompleted~Feb 2019 – ~Jan 2021 · 23 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2023 · 30 months · monthly snapshotCompleted~Jul 2023 – ~Jul 2024 · 12 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 22 months · monthly snapshotCompleted

Change History

7 versions recorded
  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jul 2023 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2023 [monthly]

    Completed PHASE3

  5. Feb 2019 — Jan 2021 [monthly]

    Completed PHASE3

Show 2 earlier versions
  1. Jun 2018 — Feb 2019 [monthly]

    Completed PHASE3

  2. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Apr 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Eastern Cooperative Oncology Group
  • National Cancer Institute (NCI)
Data source: Eastern Cooperative Oncology Group

For direct contact, visit the study record on ClinicalTrials.gov .